Agios Pharmaceuticals (AGIO) Hits New 1-Year High and Low at $89.33

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) reached a new 52-week high and low on Friday . The stock traded as low as $89.33 and last traded at $87.91, with a volume of 208507 shares changing hands. The stock had previously closed at $87.48.

Several analysts have weighed in on AGIO shares. BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a report on Tuesday, January 9th. Finally, Royal Bank of Canada upped their target price on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $87.00.

The company has a market cap of $4,834.36, a P/E ratio of -13.16 and a beta of 1.98.



Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). The company had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm’s revenue was down 56.7% on a year-over-year basis. During the same period in the previous year, the business earned ($1.34) EPS. equities research analysts expect that Agios Pharmaceuticals will post -6.25 EPS for the current year.

In related news, major shareholder Corp /De/ Celgene acquired 851,154 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were acquired at an average price of $67.00 per share, with a total value of $57,027,318.00. Following the completion of the purchase, the insider now directly owns 1,374,599 shares in the company, valued at $92,098,133. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Thursday, April 5th. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the sale, the insider now directly owns 60,196 shares in the company, valued at approximately $4,526,739.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 210,880 shares of company stock worth $16,368,948. Corporate insiders own 5.43% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Nationwide Fund Advisors lifted its position in Agios Pharmaceuticals by 37.8% during the third quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 1,740 shares during the period. Bank of New York Mellon Corp lifted its position in Agios Pharmaceuticals by 3.9% during the third quarter. Bank of New York Mellon Corp now owns 176,405 shares of the biopharmaceutical company’s stock worth $11,775,000 after buying an additional 6,632 shares during the period. Ameriprise Financial Inc. lifted its position in Agios Pharmaceuticals by 15.0% during the third quarter. Ameriprise Financial Inc. now owns 57,504 shares of the biopharmaceutical company’s stock worth $3,838,000 after buying an additional 7,510 shares during the period. Macquarie Group Ltd. purchased a new position in Agios Pharmaceuticals during the third quarter worth about $245,000. Finally, Legal & General Group Plc lifted its position in Agios Pharmaceuticals by 29.8% during the third quarter. Legal & General Group Plc now owns 16,241 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 3,724 shares during the period. 82.41% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This report was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://dakotafinancialnews.com/2018/04/13/agios-pharmaceuticals-agio-hits-new-1-year-high-and-low-at-89-33.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply